IRONDisc Medicine, Inc.

Disc Medicine, Inc. (NASDAQ: IRON) | Price: $71.53 | Today's Change: -3.51%

---

What Happened

Disc Medicine, Inc. filed an 8-K with the SEC on September 10, 2026, disclosing financial results for the second quarter of fiscal year 2026 under Items 7.01, 8.01, and 9.01. The company reported a net loss of $34,085,000 and a basic and diluted loss per share of -$2.61 for Q2 FY2026. Notably, the operating loss for the quarter reached $101,356,000, signaling a significantly elevated cost base relative to revenues — a hallmark of a clinical-stage biopharmaceutical company investing heavily in pipeline development.

---

Why It Matters

For investors, the most immediately striking figure is the $101.4 million operating loss — substantially wider than the net loss of $34.1 million, suggesting the gap is partially bridged by non-operating items (such as investment income or other adjustments), though the specific composition of those line items is not provided in the structured data from this filing. The -$2.61 EPS (both basic and diluted) reflects ongoing cash consumption that is typical for pre-revenue or early-revenue biotechs, but the scale of the operating loss warrants close attention. Investors will want to understand Disc Medicine's cash runway and whether additional capital raises are anticipated in the near term.

---

Analysis

This filing arrives at a notable moment: StockWatch published its initiating coverage on IRON on September 11, 2026 — one day after this 8-K was filed — placing the quarterly loss figures squarely in the context of fresh institutional scrutiny. The $101.4M operating loss is a significant number for a company of IRON's market profile, and the market's reaction — a 3.51% decline in today's session — suggests investors are digesting these figures with caution.

That said, for clinical-stage biotechs, operating losses of this magnitude are often a function of R&D spend intensity rather than business deterioration per se. The key questions to watch:

• Cash position and burn rate: Not provided in the structured filing data — investors should look to the full financial statements accompanying this 8-K for balance sheet detail.
• Non-operating offsets: The meaningful gap between the $101.4M operating loss and the $34.1M net loss implies notable non-operating income; understanding its composition (e.g., interest income on cash reserves) is critical for modeling runway.
• Pipeline catalysts: For a company at this stage, the investment thesis hinges far more on clinical milestones than on quarterly loss figures. Upcoming data readouts or regulatory events will likely move the stock more than the operating loss alone.

The filing date of September 10, 2026 predates today's coverage initiation, and investors should read both disclosures in conjunction to form a complete picture of where Disc Medicine stands operationally and strategically.

---

Disclaimer

This report is a news and informational summary based solely on data contained in Disc Medicine's SEC filing (8-K filed September 10, 2026) and structured XBRL facts extracted from that filing. It does not constitute investment advice, a solicitation to buy or sell securities, or an equity research recommendation of any kind. Investors should conduct their own due diligence and consult a qualified financial adviser before making any investment decision.

Existing Coverage

StockWatch has full coverage on IRON, published 2026-09-11. Read our Initiating Coverage →

Source

Filed with the SEC on 2026-09-10. Read the original filing on EDGAR: https://www.sec.gov/Archives/edgar/data/1816736/000119312526387351/iron-20260909.htm